Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-06-15

FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)

View source ↗

Summary

The FDA approved Indivior's supplemental application for SUBLOCADE (buprenorphine), resulting in regulatory action on the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUBLOCADE (buprenorphine extended-release)

Snippet

SUPPL AP for SUBLOCADE (BUPRENORPHINE)